Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...
Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University ...
Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial The data ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine ...
DALLAS - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotech company with a current market capitalization of approximately $31 million, has unveiled promising preclinical data for its drug ...
Fluoroscopy is often used to improve LP success rates in challenging cases, but reliance on fluoroscopic guidance poses cumulative radiation risks, which is particularly concerning for pediatric ...
DALLAS, Jan. 24, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the ...
Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback